FDA approves first therapy to treat patients with rare blood disorder

November 8, 2019 – Today the U.S. Food and Drug Administration granted approval to luspatercept–aamt for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. “When patients receive multiple blood transfusions, there is a risk for iron overload, which can affect many organs,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the … (leggi tutto)